Access to early stage growth capital is an ongoing challenge to the growth of Arizona’s Bioindustry. To address this challenge, AZBio, in partnership with the Opportunity Through Entrepreneurship Foundation and with support from a US. Economic Development Agency (EDA) grant has developed AZAdvances. The Marketing Consultant will work with the AZBio Team to inspire the community and engage support.Continue reading
Author Archive: AZBio
AZBio Job Opportunity: Entrepreneurial Program Grants Administrator (Post-doc)
As part of its ongoing efforts to strengthen Arizona’s Bioscience and Medtech Entrepreneurial Ecosystem, AZBio encourages qualified post-doctorate applicants to apply to join our team as a Entrepreneurial Program Grants Administrator. This is a 1-year position.Continue reading
AZBio Job Opportunity: Entrepreneur in Residence
As part of its ongoing efforts to strengthen Arizona’s Bioscience and Medtech Entrepreneurial Ecosystem, AZBio encourages qualified applicants to apply to join our team as a Bioscience Entrepreneur-in-Residence (EIR).Continue reading
Online applications for the 2021 virtual KEYS program will open on November 1 and close December 6.
2021 KEYS PROGRAM | JUNE 7 – JULY 23, 2021
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States —
— Veklury Shortened Time to Recovery By Five Days in Hospitalized COVID-19 Patients —
Calviri, Inc. Receives Exclusive Patent License to Immunosignature Technology, Strengthening Its Disease Diagnostic Capabilities
Calviri, Inc., a biotech startup focused on ending deaths from cancer, announces that Skysong Innovations, the intellectual property management company for Arizona State University (“ASU”), granted Calviri an exclusive license to ASU’s Immunosignature patent portfolio. The portfolio consists of multiple granted and pending patents for the use and optimization of immunosignatures as an antibody-based diagnostic platform in the United States and the rest of the world.Continue reading
Pfizer Creates Educational Videos as a Resource for Students and Teachers
Bite Sized Science videos are a great resource for teachers, students, and anyone who wants to learn more about how science works.Continue reading
Get Inside the Minds of Biotech Investors
Presentations at the BIO Investor Forum got inside the minds of biotech investors and delivered insights into venture capital investment trends, the outlook for biotech markets, and more!Continue reading
AZBio Opportunity Alert: 4th Quarter Savings Challenge
Learn how to improve your bottom line and be entered to win a $500 credit towards your AZBio 2021 membership.Continue reading
NIH begins large clinical trial to test immune modulators for treatment of COVID-19
The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called a “cytokine storm” — that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. The clinical trial aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays. The trial, known as ACTIV-1 Immune Modulators (IM), will determine if the therapeutics are able to restore balance to an overactive immune system.Continue reading